Bristol-Myers Squibb Co. (BMY)

Oncology Corporate Profile

Stock Performance

70.2300
-0.6300

HQ Location

345 Park Avenue
New York, NY 10154

Company Description

Bristol-Myers Squibb engages in the discovery, development, licensing, manufacture, marketing, distribution, and sale of pharmaceuticals and other health care related products worldwide. It operates in three segments: Pharmaceuticals, Nutritionals, and ConvaTec.

Website: http://www.bms.com

Brand Generic Indication
Empliciti®elotuzumabEmpliciti®is a SLAMF7-directed immunostimulatory antibody indicated in combination with lenalidomide and dexamethasone for the treatment of patients with multiple myeloma who have received one to three prior therapies.
Erbitux®cetuximabErbitux® is an epidermal growth factor receptor (EGFR) antagonist indicated for

treatment of:

Head and Neck Cancer

• Locally or regionally advanced squamous cell carcinoma of the head and neck in combination with radiation therapy.

• Recurrent locoregional disease or metastatic squamous cell carcinoma of the head and neck in combination with platinum-based therapy with 5-FU.

• Recurrent or metastatic squamous cell carcinoma of the head and neck

progressing after platinum-based therapy.


Colorectal Cancer

K-Ras mutation-negative (wild-type), EGFR-expressing, metastatic colorectal cancer as determined by FDA-approved tests

• in combination with FOLFIRI for first-line treatment

• in combination with irinotecan in patients who are refractory to irinotecan-based chemotherapy,

• as a single agent in patients who have failed oxaliplatin- and irinotecan-based chemotherapy or who are intolerant to irinotecan.

Limitation of Use: Erbitux (cetuximab) is not indicated for treatment of K-Ras mutation-positive colorectal cancer.
Opdivo®nivolumabOpdivo® is a programmed death receptor-1 (PD-1) blocking antibody indicated for the treatment of patients with:

• BRAF V600 wild-type unresectable or metastatic melanoma, as a single agent.

• BRAF V600 mutation-positive unresectable or metastatic melanoma, as a single agent. This indication is approved under accelerated approval based on progression-free survival. Continued approval for this indication may be contingent upon verification and description of clinical benefit in the confirmatory trials.

• Unresectable or metastatic melanoma, in combination with ipilimumab. This indication is approved under accelerated approval based on progression-free survival. Continued approval for this indication may be contingent upon verification and description of clinical benefit in the confirmatory trials.

• Metastatic non-small cell lung cancer and progression on or after platinum-based chemotherapy. Patients with EGFR or ALK genomic tumor aberrations should have disease progression on FDA-approved therapy for these aberrations prior to receiving OPDIVO.

• Advanced renal cell carcinoma who have received prior anti-angiogenic therapy.

• Classical Hodgkin lymphoma that has relapsed or progressed after autologous hematopoietic stem cell transplantation (HSCT) and post-transplantation brentuximab vedotin. This indication is approved under accelerated approval based on overall response rate. Continued approval for this indication may be contingent upon verification and description of clinical benefit in confirmatory trials.

• Recurrent or metastatic squamous cell carcinoma of the head and neck with disease progression on or after a platinum-based therapy.

• Locally advanced or metastatic urothelial carcinoma who have disease progression during or following platinum-containing chemotherapy and have disease progression within 12 months of neoadjuvant or adjuvant treatment with platinum-containing chemotherapy. This indication is approved under accelerated approval based on tumor response rate and duration of response. Continued approval for this indication may be contingent upon verification and description of clinical benefit in confirmatory trials.
Sprycel®dasatinibSprycel® is a kinase inhibitor indicated for:

• treatment of adults with chronic, accelerated, or myeloid or lymphoid blast phase chronic myeloid leukemia (CML) with resistance or intolerance to prior therapy including imatinib.

• treatment of adults with Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL) with resistance or intolerance to prior therapy.
Taxol®paclitaxelTaxol® is indicated as first-line and subsequent therapy for the treatment of advanced carcinoma of the ovary. As first-line therapy, TAXOL is indicated in combination with cisplatin. Taxol® is indicated for the adjuvant treatment of node-positive breast cancer administered sequentially to standard doxorubicin-containing combination chemotherapy. In the clinical trial, there was an overall favorable effect on disease-free and overall survival in the total population of patients with receptor-positive and receptor-negative tumors, but the benefit has been specifically demonstrated by available data (median follow-up 30 months) only in the patients with estrogen and progesterone receptornegative tumors. Taxol® is indicated for the treatment of breast cancer after failure of combination chemotherapy for metastatic disease or relapse within 6 months of adjuvant chemotherapy. Prior therapy should have included an anthracycline unless clinically contraindicated. Taxol®, in combination with cisplatin, is indicated for the first-line treatment of nonsmall cell lung cancer in patients who are not candidates for potentially curative surgery and/or radiation therapy. Taxol® is indicated for the second-line treatment of AIDS-related Kaposi's sarcoma.
Yervoy®ipilimumabYervoy® is a human cytotoxic T-lymphocyte antigen 4 (CTLA-4)-blocking antibody indicated for the treatment of unresectable or metastatic melanoma.

View additional information on commercial products here »

  • Brand
  • Generic
  • Investigational
Brand / Product Class Area of Study Phase Partnership
brivanibVEGFR-2 inhibitor1st line metastatic Colorectal cancerIII
brivanibVEGFR-2 inhibitor2nd line metastatic Hepatocellular carcinoma (HCC)III
brivanibVEGFR-2 inhibitorHepatocellular carcinoma (HCC)III
tanespimycin (+ bortezomib) / KOS-953Hsp90 inhibitorMultiple MyelomaIIICell Genesys
necitumumab / IMC-11F8EGFR inhibitorNon Small Cell Lung Cancer (NSCLC)IIIEli Lilly
nivolumabPD-1 inhibitorNon Small Cell Lung Cancer (NSCLC)III
nivolumab (+ ipilimumab)PD-1 inhibitorRenal cell carcinoma (RCC)III
nivolumab (+ ipilimumab)PD-1 inhibitorRenal cell carcinoma (RCC)III
Cometriq® / cabozantinib / XL184multiple tyrosine kinase inhibitor (MET and RET)2nd line metastatic castrate-resistant prostate cancer (CRPC)IIIExelixis
Cometriq® / cabozantinib / XL184multiple tyrosine kinase inhibitor (MET and RET)Hepatocellular carcinoma (HCC)IIIExelixis
Cometriq® / cabozantinib / XL184multiple tyrosine kinase inhibitor (MET and RET)Medullary Thyroid cancer (MTC)IIIExelixis
Erbitux® / cetuximabanti-EGFR monoclonal antibody1st line metastatic Colorectal cancerIIIEli Lilly
Erbitux® / cetuximabanti-EGFR monoclonal antibodyNon Small Cell Lung Cancer (NSCLC)IIIEli Lilly
Ixempra® / ixabepiloneepothiloneAdjuvant Breast cancerIII
Sprycel® / dasatinibdual kinase inhibitor for BCR-ABL & Src BCR-ABLChronic Myelogenous Leukemia (CML)III
Yervoy® / ipilimumab / MDX-010anti-CTLA4 monoclonal antibody (humanized)2nd line metastatic MelanomaIII
Yervoy® / ipilimumab / MDX-010anti-CTLA4 monoclonal antibody (humanized)Adjuvant MelanomaIII
Yervoy® / ipilimumab / MDX-010anti-CTLA4 monoclonal antibody (humanized)Head & Neck cancerIII
BMS-844203 (+ irinotecan and 5-FU and leucovorin (FOLFIRI))VEGF R-2 adnectin1st line metastatic Colorectal cancerII
interleukin 21 (IL-21)immunotherapy1st line metastatic MelanomaII
BMS-690514VEGFR2 inhibitor2nd line metastatic Breast cancerII
BMS-844203VEGF R-2 adnectin2nd line metastatic Glioblastoma Multiforme (GBM)II
tanespimycin / KOS-953Hsp90 inhibitorBreast cancerII
BMS-754807dual IGF-1R/insulin receptor (IR) kinase inhibitorBreast cancerII
nivolumab (+ pillimumab)PD-1 inhibitorGlioblastoma Multiforme (GBM)II
nivolumabPD-1 inhibitorGlioblastoma Multiforme (GBM)IINULl
nivolumab (+ TG4010)immunotherapyNon Small Cell Lung Cancer (NSCLC)IITransgene
BMS-690514VEGFR2 inhibitorNon Small Cell Lung Cancer (NSCLC)II
BMS-844203VEGF R-2 adnectinNon Small Cell Lung Cancer (NSCLC)II
KOS-1584epothiloneNon Small Cell Lung Cancer (NSCLC)II
tanespimycin (+ trastuzumab) / KOS-953Hsp90 inhibitorProstate cancerII
nivolumabPD-1 inhibitorRenal cell carcinoma (RCC)II
interleukin 21 (IL-21) (+ sorafenib)immunotherapyRenal cell carcinoma (RCC)II
brivanibVEGFR-2 inhibitorSarcomaII
tanespimycin (+ trastuzumab) / KOS-953Hsp90 inhibitorThyroid cancerII
KOS-1584epothiloneVarious cancer typesII
Cometriq® / cabozantinib / XL184multiple tyrosine kinase inhibitor (MET and RET)1st line metastatic Breast cancerIIExelixis
Cometriq® / cabozantinib / XL184multiple tyrosine kinase inhibitor (MET and RET)2nd line metastatic Glioblastoma Multiforme (GBM)IIExelixis
Cometriq® / cabozantinib / XL184multiple tyrosine kinase inhibitor (MET and RET)2nd line metastatic Ovarian cancerIIExelixis
Cometriq® / cabozantinib / XL184multiple tyrosine kinase inhibitor (MET and RET)Non Small Cell Lung Cancer (NSCLC)IIExelixis
Cometriq® / cabozantinib / XL184multiple tyrosine kinase inhibitor (MET and RET)Various cancer typesIIExelixis
Erbitux® / cetuximabanti-EGFR monoclonal antibodyGastric cancerIIEli Lilly
Ixempra® / ixabepiloneepothiloneEndometrial cancerII
Ixempra® / ixabepiloneepothiloneNon Small Cell Lung Cancer (NSCLC)II
Ixempra® (+ Avastin®) / ixabepilone (+ bevacizumab)epothilone1st line metastatic Breast cancerII
Sprycel® / dasatinibdual kinase inhibitor for BCR-ABL & Src BCR-ABLNon Small Cell Lung Cancer (NSCLC)II
Yervoy® / ipilimumab / MDX-010anti-CTLA4 monoclonal antibody (humanized)Brain Metastases from MelanomaII
Yervoy® / ipilimumab / MDX-010anti-CTLA4 monoclonal antibody (humanized)Non Small Cell Lung Cancer (NSCLC)II
Yervoy® / ipilimumab / MDX-010anti-CTLA4 monoclonal antibody (humanized)Pancreatic cancerII
Yervoy® / ipilimumab / MDX-010anti-CTLA4 monoclonal antibody (humanized)Prostate cancerII
MDX-1203anti-CD70 monoclonal antibody (humanized)1st line metastatic Renal cell carcinoma (RCC)I
MDX-1203anti-CD70 monoclonal antibody (humanized)2nd line metastatic b-cell Non-Hodgkin's Lymphoma (b-NHL)I
BMS-936564 (MDX-1338)anti-CXCR4Acute Myelogenous Leukemia (AML)I
MDX-1342anti-CD19 monoclonal antibody (humanized)Chronic Lymphocytic Leukemia (CLL)I
MDX-1411anti-CD70 monoclonal antibody (humanized)Clear cell Renal cell carcinoma (RCC)I
nivolumabPD-1 inhibitorHepatocellular carcinoma (HCC)I
MDX-1401anti-CD30 monoclonal antibody (humanized, non-fucosylated)Hodgkin's LymphomaI
nivolumab (+ CB-839)PD-1 inhibitorMelanomaICalithera
nivolumab (+ ipilimumab)PD-1 inhibitorNon Small Cell Lung Cancer (NSCLC)I
nivolumab (+ CB-839)PD-1 inhibitorNon Small Cell Lung Cancer (NSCLC)ICalithera
interleukin 21 (IL-21) (+ ritiximub)immunotherapyNon-Hodgkin's Lymphoma (NHL)I
MDX-1411anti-CD70 monoclonal antibody (humanized)Non-Hodgkin's Lymphoma (NHL)I
nivolumab (+ CB-839)PD-1 inhibitorRenal cell carcinoma (RCC)ICalithera
nivolumab (+ ipilimumab)PD-1 inhibitorSmall Cell Lung Cancer (SCLC)I
UnnamedMET kinase inhibitorVarious cancer typesI
UnnamedSMO inhibitorVarious cancer typesI
nivolumab / BMS-936558 / MDX1106PD-1 inhibitorVarious cancer typesI
Unnamedanti-IGF-1R monoclonal antibodyVarious cancer typesI
MDX-1106 (ONO-4538)anti-PD1 monoclonal antibody (humanized)Various cancer typesIOno Pharmaceutical
MDX-1105anti-PD-L1 monoclonal antibody (humanized)Various cancer typesI
UnnamedCdc7 inhibitorVarious cancer typesI
epothilone-folate / BMS-753493epothiloneVarious cancer typesI
UnnamedErbB/VEGF receptor inhibitorVarious cancer typesI
UnnamedHsp90 inhibitorVarious cancer typesI
Unnamedandrogen receptor antagonistVarious cancer typesI
Unnamedanti-CD137 monoclonal antibodyVarious cancer typesI
nivolumab (+ varlilumab)PD-1 inhibitorVarious cancer typesI
Glypican3-ADCantibody drug conjugate (ADC)Various cancer typesI
Cometriq® / cabozantinib / XL281multiple tyrosine kinase inhibitor (MET and RET)1st line metastatic Colorectal cancerIExelixis
Cometriq® / cabozantinib / XL184multiple tyrosine kinase inhibitor (MET and RET)Multiple MyelomaIExelixis
Opdivo® / nivolumabPD-1 inhibitorBladder cancerI
Sprycel® / dasatinibdual kinase inhibitor for BCR-ABL & Src BCR-ABLColorectal cancerI
Sprycel® / dasatinibdual kinase inhibitor for BCR-ABL & Src BCR-ABLGlioblastoma Multiforme (GBM)I
Sprycel® / dasatinibdual kinase inhibitor for BCR-ABL & Src BCR-ABLMesotheliomaI
Sprycel® / dasatinibdual kinase inhibitor for BCR-ABL & Src BCR-ABLMyelodysplastic Syndrome (MDS)I
urelumab (+ nivolumab) / BMS-663513anti-4-1BB antibodyVarious cancer types
FLX925flt-3 + cdk4/6 inhibitorVarious cancer types
Opdivo® / nivolumab (+ ocuplumab)PD-1 inhibitorVarious cancer types
KOS-1803epothiloneVarious cancer typesPreclinical
KOS-2464nuclear export inhibitors (NEI)Various cancer typesPreclinical

View additional information on product candidates here »

Source: http://www.bms.com

Recent News Headlines

Bristol-Myers Squibb to Present New Data at the 58th Annual Meeting & Exposition of the American Society of Hematology Demonstrating Research Advancements in Immuno-Oncology and Across Multiple Blood Cancers

11/3/2016 11:34 am

(BMS) Nov 3, 2016 - Data to be presented across multiple blood cancer types, including classical Hodgkin lymphoma, chronic myeloid leukemia and multiple myeloma; new data presentations showing the safety and efficacy of Opdivo (nivolumab), Sprycel (dasatinib) and Empliciti (elotuzumab); first disclosure of preliminary results from Phase 1/2 study of Opdivo in combination with ADCETRIS (brentuximab vedotin) in patients with relapsed or refractory classical Hodgkin lymphoma.

New Data Presentations at SITC 2016 Annual Meeting Highlight Bristol-Myers Squibb’s Leadership in Advancing the Science of Immuno-Oncology Combinations

11/2/2016 11:12 am

(BMS) Nov 2, 2016 - Interim data evaluating the efficacy of lirilumab, an anti-KIR antibody, in combination with Opdivo (nivolumab), a PD-1 inhibitor, will be presented in a late-breaking oral session; late-breaking data from CheckMate -032 studying Opdivo plus Yervoy (ipilimumab) in metastatic urothelial carcinoma will also be presented.

Bristol-Myers Squibb’s Yervoy (ipilimumab) Awarded Prix Galien USA Discovery of the Decade

10/31/2016 10:39 am

(BMS) Oct 28, 2016 - Bristol-Myers Squibb Company announced today that it received the Prix Galien USA Discovery of the Decade biotech award for Yervoy (ipilimumab), the Company’s recombinant, human monoclonal antibody.

New Bristol-Myers Squibb Research on Opdivo (nivolumab) Monotherapy and in Combination With Yervoy (ipilimumab) at SMR 2016 Congress Reinforces Immuno-Oncology Leadership and Scientific Expertise in Melanoma

10/31/2016 10:30 am

(BMS) Oct 31, 2016 - Bristol-Myers Squibb Company today announced new data presentations from studies evaluating Opdivo (nivolumab) as monotherapy or in combination with Yervoy (ipilimumab) in the treatment of melanoma.

Bristol-Myers Squibb’s Coast 2 Coast 4 Cancer Ride Raises Over $1 Million for Cancer Research

10/24/2016 11:56 am

(BMS) Oct 24, 2016 - Bristol-Myers Squibb’s Coast 2 Coast 4 Cancer has raised more than $1,050,000 to support Stand Up To Cancer’s collaborative cancer research programs. In this third year of the relay, six teams of BMS employees -- with 80 employees in total -- set out on September 7 to bike 2,800 miles in 21 days from the Oregon Coast to the New Jersey shore to support Stand Up To Cancer, whose collaborative “Dream Teams” of scientific researchers are working together to accelerate cancer research and to provide innovative treatments to patients faster. Bristol-Myers Squibb matched all money raised by the cyclists, dollar-for-dollar, up to $500,000.

Bristol-Myers Squibb Foundation Joins White House Cancer Moonshot

10/18/2016 11:41 am

(BMS) Oct 17, 2016 - Today the Bristol-Myers Squibb Foundation joins the White House Cancer Moonshot initiative through its commitment to addressing health disparities in cancer care.

Bristol-Myers Squibb Receives Positive CHMP Opinion for Opdivo (nivolumab) for the Treatment of Adult Patients With Relapsed or Refractory Classical Hodgkin Lymphoma After Autologous Stem Cell Transplant and Treatment With Brentuximab Vedotin

10/14/2016 11:06 am

(StreetInsider) Oct 14, 2016 - First PD-1 inhibitor in a hematologic malignancy to receive positive CHMP opinion; CHMP decision based on overall response rate demonstrated by data from two trials, CheckMate -205 and CheckMate -039.

Bristol-Myers Asked to Seek Special Coverage for Opdivo in U.K.

10/14/2016 11:02 am

(Bloomberg) Oct 13, 2016 - Bristol-Myers Squibb Co.’s Opdivo lung-cancer treatment isn’t cost-effective for all patients, and the company should seek to make it accessible to some through a special U.K. government program, the country’s health-cost regulator said.

Bristol-Myers Partner Ono Drops as Cancer Drug Data Disappoint

10/11/2016 12:12 pm

(Bloomberg) Oct 10, 2016 - Ono Pharmaceutical Co. shares dropped in Japan trading after its partner Bristol-Myers Squibb Co. released study results for its immune-based therapy Opdivo that fell short of already low expectations in a lung cancer trial that studied wider use of the drug.

Bristol-Myers Squibb Presents Results From CheckMate -026, a Phase 3 Study of Opdivo (nivolumab) Monotherapy Versus Chemotherapy as First-Line Therapy in a Broad PD-L1 Positive Population With Advanced Lung Cancer

10/10/2016 09:50 am

(BMS) Oct 9, 2016 - Bristol-Myers Squibb Company announced today the final primary analysis of CheckMate -026, a trial investigating the use of Opdivo (nivolumab) monotherapy as first-line therapy in patients with advanced non-small cell lung cancer (NSCLC) whose tumors expressed PD-L1 ?1%.

Merck Solidifies Lung Cancer Immunotherapy Lead Over Bristol-Myers Squibb

10/10/2016 09:42 am

(TheStreet) Oct 9, 2016 - Merck's Keytruda works in first-line lung cancer, Bristol's Opdivo does not.

Bristol-Myers Lung-Cancer Drug Disappoints in Trial Analysis

10/10/2016 06:24 am

(Bloomberg) Oct 9, 2016 - Bristol-Myers Squibb Co.’s immune-based therapy Opdivo fell short of already low expectations in study results that throw into question whether the drug can help lung-cancer patients who’ve just been diagnosed.

New Research From Bristol-Myers Squibb at ESMO 2016 Congress Reinforces Leadership in Immuno-Oncology and Differentiated Research Approach

10/4/2016 12:12 pm

(Bristol-Myers Squibb) Oct 3, 2016 - Broad set of data across eight tumor types evaluating Opdivo and Yervoy, as monotherapy or in combination, to be presented; first disclosure of novel assets, including lirilumab in combination with Opdivo or Yervoy in squamous cell carcinoma of the head and neck, and fucosyl GM1 in small cell lung cancer; new Opdivo data in advanced bladder cancer to be highlighted, and first presentation of overall survival with Yervoy in adjuvant melanoma; Immuno-Oncology strategy update to be provided at Investor Teleconference.

Bavarian Nordic Announces Drug Supply Agreement With Bristol-Myers Squibb For NSCLC Clinical Study

8/15/2016 11:24 am

(Bavarian Nordic) Aug 15, 2016 - Bavarian Nordic A/S today announced the signature of a drug supply agreement with Bristol-Myers Squibb (BMS). Based on the agreement, BMS will supply OPDIVO® (nivolumab) to Bavarian Nordic for use in a clinical study.

AVEO Initiates the Evaluation of Tivozanib in Combination with Bristol-Myers Squibb’s Opdivo® (nivolumab) in Advanced Renal Cell Carcinoma

8/15/2016 11:18 am

(MarketWatch) Aug 15, 2016 - AVEO Oncology today announced the initiation of a clinical evaluation of AVEO’s oral, once-daily, vascular endothelial growth factor (VEGF) tyrosine kinase inhibitor (TKI), tivozanib, in combination with Bristol-Myers Squibb’s anti-PD-1 therapy, Opdivo® (nivolumab), in advanced renal cell carcinoma (RCC).

Bristol-Myers Squibb Reacquires Rights To ASLAN002 (BMS777607) in Asia From ASLAN

8/11/2016 12:14 pm

(ASLAN) Aug 10, 2016 - ASLAN Pharmaceuticals, a biotech company focused on the development of immunotherapies and targeted agents for Asia-prevalent tumour types, today announced that Bristol-Myers Squibb will reacquire the rights to ASLAN002 (BMS777607) in China, Australia, Korea, Taiwan and other Asian territories.

Bristol-Myers Squibb's Defeat Is A Victory For Personalized Medicine

8/8/2016 11:18 am

(Forbes) Aug 6, 2016 - Yesterday, shares of drug giant Bristol-Myers Squibb fell 16% after its breakthrough cancer drug, Opdivo, failed to slow tumor growth in previously untreated patients with non-small cell lung cancer.

Bristol-Myers Executives: We Took A Bold Risk With Failed Lung Cancer Study

8/8/2016 11:17 am

(Forbes) Aug 5, 2016 - This morning, Bristol-Myers Squibb shocked Wall Street and the world of cancer medicine with the news that its drug Opdivo had failed to show a benefit as a first choice of treatment in non-small cell lung cancer.

Bristol-Myers Investors Feel the Harsh Downside of Cancer Bet

8/8/2016 11:16 am

(Bloomberg) Aug 5, 2016 - For almost four years, Bristol-Myers Squibb Co. investors have profited handsomely thanks to the company’s sharp focus on cancer. On Friday, they felt the other side of that concentrated bet.

Bristol-Myers' Opdivo Fails Lung Cancer Trial; Shares Plunge

8/5/2016 10:59 am

(Reuters) Aug 5, 2016 - Bristol-Myers Squibb Co said its blockbuster Opdivo immunotherapy failed to slow progression of symptoms in previously untreated patients with advanced lung cancer in a late-stage study, a major setback expected to benefit Merck & Co's rival medicine.

Bristol-Myers Squibb Announces New Research Collaboration with Janssen in Immuno-Oncology Focused on Lung Cancer

7/26/2016 07:12 am

(Yahoo! Finance) July 26, 2016 - Bristol-Myers Squibb Company today announced a new clinical research collaboration with Janssen Biotech, Inc. to evaluate Bristol-Myers Squibb’s Immuno-Oncology (I-O) agent Opdivo (nivolumab) and Janssen’s Live Attenuated Double–Deleted (LADD) Listerial monocytogenes cancer immunotherapy, expressing mesothelin and EGFRvIII (JNJ-64041757), in patients with non-small cell lung cancer (NSCLC).

AbbVie Partners With Bristol-Myers In Combo Study Of Cancer Drugs

7/25/2016 11:48 am

(BioPharma Dive) July 25, 2016 - AbbVie will test its experimental lung cancer drug Rova-T in combination with two immunotherapies from Bristol-Myers Squibb in an early-stage trial in small cell lung cancer (SCLC), the companies said Monday.

Bristol-Myers Squibb Appoints Fouad Namouni, M.D., Oncology Development Head

7/25/2016 11:08 am

(BMS) July 25, 2016 - Bristol-Myers Squibb Company today announced that Fouad Namouni, M.D., has been appointed Oncology Development Head, effective July 25, 2016.

AbbVie and Bristol-Myers Squibb Announce Oncology Clinical Collaboration to Evaluate the Combination of Rova-T plus Opdivo and Opdivo + Yervoy Regimen

7/25/2016 07:06 am

(BMS) July 25, 2016 - AbbVie and Bristol-Myers Squibb Company today announced a clinical trial collaboration to evaluate the safety, tolerability and efficacy of AbbVie’s investigational biomarker-specific antibody drug conjugate Rova-T (rovalpituuzumab tesirine) in combination with Bristol-Myers Squibb’s Opdivo (nivolumab) and Opdivo + Yervoy (ipilimumab) regimen as a treatment for relapsed extensive-stage small cell lung cancer (SCLC).

Bristol-Myers Squibb Announces Regulatory Updates for Opdivo (nivolumab) in Previously Treated Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck

7/18/2016 06:47 am

(BMS) July 18, 2016 - Bristol-Myers Squibb Company announced today U.S. and European marketing applications to expand the use of Opdivo for patients with previously treated recurrent or metastatic squamous cell carcinoma of the head and neck (SCCHN) were accepted for filing by the U.S. Food and Drug Administration (FDA) and validated by the European Medicines Agency (EMA).

At Cancer Moonshot Summit, Vice President Biden Announces New Actions to Accelerate Progress Toward Ending Cancer As We Know It

6/29/2016 12:03 pm

(WhiteHouse.gov) June 28, 2016 - Today, the Cancer Moonshot is hosting a summit at Howard University, in Washington, D.C. as part of a national day of action that also includes more than 270 events in communities across the United States.

How Telemedicine Is Changing Health Care

6/27/2016 12:00 pm

(Wall Street Journal) June 26, 2016 - The revolution is finally here—raising a host of questions for regulators, providers, insurers and patients.

In Letter to Franken, FDA Defends Handling Of Medtronic's Infuse Study

6/23/2016 11:04 am

(Minneapolis Star Tribune) June 22, 2016 - The U.S. Food and Drug Administration is defending a decision to accept more than 1,000 patient injury reports from Medtronic in summary form, years after they were supposed to be submitted.

ESMO 2016: From Disease Treatment to Patient Care

6/14/2016 12:00 pm

(ESMO) June 13, 2016 - Nearly 2,900 abstracts were submitted for inclusion within the ESMO 2016 Congress, marking a 70% increase over the past six years and confirming the ESMO Congress as the leading oncology event in Europe.

Molecular Imaging of Neuroendocrine Tumors Optimizes Radiotherapy Dose

6/14/2016 11:05 am

(SNMMI) June 13, 2016 — Study shows the use of PET and SPECT tailors radionuclide treatment for neuroendocrine cancer patients and reduces the risk of toxicity.

New York Poised to Expand Access to Breast Cancer Screening

6/13/2016 12:01 pm

(ABC News/Associated Press) June 13, 2016 - New York is poised to expand access to breast cancer screening under an agreement reached by top state lawmakers and Democratic Gov. Andrew Cuomo, who made combating the cancer a priority after the successful cancer treatment of his girlfriend, Food Network star Sandra Lee.

ARIAD Announces Long-Term Safety and Efficacy Data of Ponatinib from Phase 2 Pace Clinical Trial

6/13/2016 12:00 pm

(NASDAQ) June 13, 2016 - ARIAD Pharmaceuticals, Inc. today announced long-term follow-up data from its pivotal Phase 2 PACE clinical trial of Iclusig® (ponatinib), its approved BCR-ABL inhibitor, in heavily pretreated patients with resistant or intolerant chronic myeloid leukemia (CML) or Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL).

Basilea Reports Presentation Of Data On Clinical Oncology Programs BAL101553 and BAL3833 at ASCO Meeting

6/9/2016 11:01 am

(Basilea Pharmaceutica) June 9, 2016 - Basilea Pharmaceutica Ltd. announced today that the final clinical data from the first-in-human phase 1/2a study with the intravenous (i.v.) form of its tumor checkpoint controller BAL101553 were presented at the American Society of Clinical Oncology (ASCO) annual meeting in Chicago, USA, on June 3-7, 2016.

The US Oncology Network Holds Intensive Boot Camp to Prepare Oncology Practices for July Launch of Oncology Care Model (OCM)

6/8/2016 11:04 am

(McKesson) June 8, 2016 - Training program provides OCM tools, technology and experience, preparing practice teams for July 1st go-live.

ASCO: Extended PFS Seen With Early Myeloma Tx

6/7/2016 02:01 pm

(MedPage Today) June 7, 2016 - Multiple myeloma patients who have relapsed appear to achieve extended progression-free survival if they are treated with a carfilzomib-based 3-drug combination therapy after their first post-relapse line of treatment, researchers suggested here.

Biden, Cancer Groups Call for Collaboration to Hasten Advances

6/7/2016 02:00 pm

(Bloomberg) June 6, 2016 - Vice President Joe Biden called on cancer researchers and health organizations to set aside individual goals in treatment and research to work together on fighting the second-leading cause of death in the U.S.

AstraZeneca and Foundation Medicine Enter Strategic Collaboration for Lynparza Companion Diagnostic Assay

6/5/2016 06:03 pm

(AstraZeneca) June 4, 2016 - Foundation Medicine, Inc. and AstraZeneca today announced that they have entered into a definitive agreement to develop a novel companion diagnostic assay for Lynparza (olaparib) to support its global development program.

MD Anderson Study Identifies Significant Cost Differences Between Breast Cancer Chemotherapy Regimens

6/5/2016 06:03 pm

(MD Anderson) June 4, 2016 - Costs associated with different breast cancer chemotherapy regimens can vary significantly, regardless of effectiveness, according to new research.

Exelixis Announces Genentech Presentation of Preliminary Phase 1B Trial Results for the Combination of Cobimetinib and Atezolizumab at ASCO 2016 Annual Meeting

6/5/2016 06:01 pm

(Yahoo! Finance) June 5, 2016 - Exelixis, Inc. today announced that its collaborator Genentech, a member of the Roche Group, will present preliminary results from a phase 1b clinical trial evaluating the safety and clinical activity of cobimetinib, an Exelixis-discovered MEK inhibitor, in combination with atezolizumab, an anti-PD-L1 antibody discovered and developed by Genentech, in patients with metastatic colorectal cancer (CRC).

Long-Term Survival and Improvement in Quality of Life Observed with Opdivo® (nivolumab) in Advanced Renal Cell Carcinoma Patients Based on New Data Presented at the 2016 ASCO Annual Meeting

6/5/2016 06:01 pm

(BMS) June 5, 2016 - Bristol-Myers Squibb Company announced today new long-term overall survival (OS) results from two dose-ranging studies, the Phase 1 CA209-003 study and the Phase 2 CA209-010 study, evaluating Opdivo in patients with previously treated advanced renal cell carcinoma (RCC).

Elderly Patients With Glioblastoma Live Longer With Chemoradiation Using Temozolomide

6/5/2016 06:00 pm

(2016 ASCO Annual Meeting) June 5, 2016 – A Canadian-led randomized phase III trial found that adding temozolomide (Temodar) chemotherapy during short-course radiation therapy, followed by monthly maintenance doses of temozolomide, significantly improved survival of elderly patients with glioblastoma, reducing the risk of death by 33%.

Double Stem-Cell Transplant Improves Outcomes for Children with High-Risk Neuroblastoma

6/5/2016 06:00 pm

(2016 ASCO Annual Meeting) June 5, 2016 – A National Cancer Institute (NCI) funded phase III trial performed by the Children's Oncology Group found that adding a second autologous stem-cell transplant (ASCT, a transplant that uses the patient's own stem cells) to standard therapy improves outcomes for patients.

Escend Pharmaceuticals, Inc. Receives Orphan Drug Designation from the US Food and Drug Administration (FDA) for ES-3000 its Lead Compound in the Treatment of Chronic Myeloid Leukemia (CML)

6/4/2016 05:05 pm

(The Business Journals) June 2, 2016 - Escend Pharmaceuticals, Inc. announced today that its lead compound, ES-3000, has received orphan drug designation from the U.S. Food and Drug Administration (FDA) for the treatment of chronic myeloid leukemia (CML).

Lexicon Announces The Launch Of Aboutcarcinoid.com To Provide Carcinoid Syndrome Disease Education To Patients, Caregivers And Physicians

6/4/2016 05:05 pm

(StreetInsider) June 2, 2016 - Lexicon Pharmaceuticals, Inc. today announced the launch of www.aboutcarcinoid.com to provide carcinoid syndrome disease education to patients, caregivers and physicians.

AbbVie Lays Out Long-Term Vision in Biotech Firm’s First R&D Day

6/4/2016 05:05 pm

(Bloomberg) June 3, 2016 - AbbVie has doubled down on cancer, buying Pharmacyclics Inc. last year for its blood cancer drug Imbruvica and, more recently, Stemcentrx Inc. for its experimental drugs targeting solid tumors.

Cancer Cell Therapies Could Be Approved Next Year: Juno, Kite Pharma

6/4/2016 05:04 pm

(Reuters) June 4, 2016 - A new wave of experimental cancer drugs that directly recruit the immune system's powerful T cells could begin reaching patients next year, according to companies presenting new data at the annual meeting of the American Society of Clinical Oncology.

Amgen Announces Launch Of KYPROLIS® (carfilzomib) CENTRAL, An Online News Resource Demonstrating The Impact Of Relapsed Multiple Myeloma On The Lives Of Patients And Caregivers

6/4/2016 05:04 pm

(NASDAQ) June 3, 2016 - Amgen today announced the launch of KYPROLIS CENTRAL, an online media resource about the impact of living with relapsed or refractory multiple myeloma.

Kangmei Healthcare Cloud Service Co to Launch Cancer Therapy Management Services

6/4/2016 05:04 pm

(Yahoo! Finance) June 3, 2016 - Cloud EHR-based bi-lingual service platform for chinese-speaking cancer patients announced at 2016 ASCO Annual Meeting.

Roche Sues India’s Drug Regulator Over Avastin ‘Similar Biologics’

6/4/2016 05:04 pm

(GaBI) June 3, 2016 - Switzerland-based drug giant Roche has sued the Drug Controller General of India (DCGI) in the Delhi High Court over ‘similar biologic’ versions of its cancer blockbuster Avastin (bevacizumab).

Halozyme Presents Stage One Efficacy And Safety Analysis Of Phase 2 Clinical Study In Metastatic Pancreatic Cancer Patients Treated With PEGPH20

6/4/2016 05:02 pm

(4-traders) June 4, 2016 - Halozyme Therapeutics, Inc. today announced results from a final analysis of 135 metastatic pancreatic cancer patients who were treated in Stage One of HALO 109-202, a phase 2 clinical study of its investigational new drug PEGPH20 in combination with ABRAXANE (nab-paclitaxel) and gemcitabine (PAG arm) as compared to ABRAXANE and gemcitabine alone (AG arm).